Whalesbook
West Africa Grapples with Tapentadol Epidemic
West Africa is facing a growing public health crisis as potent tapentadol tablets, mainly produced in India, are driving a deadly opioid epidemic. These unapproved drugs, often mislabeled, are easily accessible and increasingly mixed with 'kush,' a dangerous synthetic drug cocktail. Millions of dollars worth of these high-strength pills are entering countries like Nigeria, Sierra Leone, and Ghana, where even low doses are not medically approved. Health officials note tapentadol's significant role in the widespread use of kush, which has prompted national emergency declarations in Liberia and Sierra Leone.
Devastating Human Cost
The human toll is severe. In Freetown, Sierra Leone, over 400 deaths in three months were linked to kush mixed with tapentadol or other potent opioids. Ansu Konneh, director of mental health at Sierra Leone's social welfare ministry, stated that 90 percent of patients in rehabilitation centers show signs of combined substance abuse. The misuse of tapentadol extends beyond addiction, including its use for performance enhancement in strenuous labor, appetite suppression, and even aiding criminal activities like kidnapping, highlighting its multifaceted societal impact.
Regulatory Evasions Continue
India's declaration of a "zero-tolerance" policy and a ban on tapentadol combination exports in February 2025, following a BBC investigation, has had limited effect on the core problem. The main trade involves pure tapentadol, which researchers believe was largely unaffected by the ban on combinations. Shipping data and seizure records confirm ongoing monthly exports of high-strength tapentadol tablets from India. Many shipments are deceptively labeled as "Harmless Medicines for Human Consumption." Companies such as Gujarat Pharmaceuticals, McW Healthcare, and Syncom Formulations, which reportedly shipped nearly $15 million in tapentadol after the crackdown, exemplify the continued flow of these drugs.
Exploiting Vulnerabilities
Manufacturers appear to be exploiting regulatory loopholes and less stringent oversight in parts of West Africa, leveraging India's position as a major generic drug producer. Confusion between tapentadol and the less potent tramadol further aids illicit circulation. Despite India classifying tapentadol as a controlled narcotic in 2018, its export persists, often bypassing restrictions. The availability of pills with dosages like 225mg and 250mg, which lack official approval in any country for general use, suggests a deliberate disregard for safety protocols by some exporters, contributing to a "sense of impunity."